Halozyme Therapeutics
HALO
Hutchmed (China)
HCM
Lantheus
LNTH
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Teradata Corp
TDC
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | ||||||||||
Net income from continuing operations | ---- | ---- | 6,171.79%12.23M | 45.03%-36.83M | ---- | ---- | ---- | 102.86%195K | -73.57%-67.01M | ---- |
Change In working capital | 37.40%-5.97M | 152.24%24.22M | -154.90%-25.34M | -76.57%10.37M | 20.82%76.2M | -265.29%-9.53M | -54.32%-46.36M | -171.90%-9.94M | 318.26%44.25M | 15,907.02%63.07M |
-Change in receivables | ---- | ---- | ---- | -484.41%-27.57M | ---- | ---- | ---- | ---- | 119.31%7.17M | ---- |
-Change in inventory | ---- | ---- | ---- | 71.47%-1.84M | ---- | ---- | ---- | ---- | -1,188.03%-6.45M | ---- |
-Change in other current liabilities | ---- | ---- | ---- | -8.61%39.78M | ---- | ---- | ---- | ---- | 167.41%43.53M | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 517.08%9.33M | 115.94%6.86M | -34.52%-13.11M | -24.12%4.88M | 39.12%59.91M | 80.34%-2.24M | -33.43%-43.04M | -239.10%-9.75M | 118.15%6.44M | 2,728.82%43.06M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | ||||||||||
Net PPE purchase and sale | ---- | ---- | ---- | -29.97%-17.11M | ---- | ---- | ---- | ---- | 1.01%-13.16M | ---- |
Net intangibles purchase and sale | ---- | ---- | ---- | -22.20%-33.87M | ---- | ---- | ---- | ---- | -74.05%-27.71M | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 10.06%-11.32M | 46.19%-7.78M | 45.49%-7.59M | -24.70%-50.97M | 29.61%-10.01M | -34.58%-12.58M | -62.45%-14.46M | -65.57%-13.93M | -87.68%-40.87M | -34.22%-14.21M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | ||||||||||
Net issuance payments of debt | ---- | ---- | ---- | --24.47M | ---- | ---- | ---- | ---- | --0 | ---- |
Net common stock issuance | ---- | ---- | ---- | --47.64M | ---- | ---- | ---- | ---- | --0 | ---- |
Net other financing activities | ---- | ---- | ---- | 50.00%-2.5M | ---- | ---- | ---- | ---- | -500,100.00%-5M | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -137.80%-9.31M | -101.53%-476K | -112.56%-1.32M | 624.85%53.91M | -657.34%-12.38M | 2,255.69%24.62M | 2,751.45%31.18M | 265.97%10.49M | -111.46%-10.27M | -483.57%-1.63M |
Net cash flow | ||||||||||
Beginning cash position | 183.06%36.75M | -1.80%38.36M | 14.29%59.55M | -45.79%52.1M | -9.40%22.68M | -72.08%12.98M | -56.07%39.06M | -45.79%52.1M | 53.94%96.11M | -76.83%25.03M |
Current changes in cash | -215.21%-11.29M | 94.70%-1.39M | -67.00%-22.02M | 117.50%7.83M | 37.90%37.53M | 144.82%9.8M | 37.84%-26.31M | -70.68%-13.19M | -238.00%-44.71M | 317.56%27.21M |
Effect of exchange rate changes | 67.29%-35K | -187.82%-209K | 465.99%832K | -153.92%-378K | -361.97%-656K | -127.79%-107K | 390.24%238K | -72.78%147K | -45.15%701K | -124.83%-142K |
End cash Position | 12.13%25.43M | 183.06%36.75M | -1.80%38.36M | 14.29%59.55M | 14.29%59.55M | -9.40%22.68M | -72.08%12.98M | -56.07%39.06M | -45.79%52.1M | -45.79%52.1M |
Free cash flow | 517.08%9.33M | 115.94%6.86M | -34.52%-13.11M | -33.83%-46.09M | 308.74%8.94M | 80.34%-2.24M | -33.43%-43.04M | -239.10%-9.75M | 46.75%-34.44M | 107.08%2.19M |
Currency Unit | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK | SEK |